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 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
treatment with onabotulinumtoxinA improves the quality of life in patients with urinary 
incontinence not adequately controlled with anticholinergics. 
 
STUDY DESIGN: Review of three English language, randomized controlled trials published in 
2013. 
 
DATA SOURCES: Randomized, double-blind, controlled clinical trials comparing 
onabotulinumtoxinA intradetrusor injections with saline placebo.  All articles were found using 
PubMed. 
 
OUTCOMES MEASURED: Each of the three trials assessed the patient’s quality of life after 
treatment with onabotulinumtoxinA using the following assessment tools: Incontinence Quality 
of Life Questionnaire (I-QOL), Modified Overactive Bladder Patient Satisfaction with Treatment 
Questionnaire (OAB-PSTQ), King’s Health Questionnaire (KHQ), Patient Global Assessment 
(PGA), and Treatment Benefit Scale. 
 
RESULTS: Both the Chancellor et al. and the Sussman et al. studies found a statistically 
significant improvement in the change from baseline in the I-QOL and OAB-PSTQ for the 
patients who received onabotulinumtoxinA compared to placebo (p value < 0.001).  Nitti et al. 
demonstrated an improvement range of 19.6 to 23.9 ± SD change from baseline in the I-QOL 
score for the onabotulinumtoxinA treatment group.  60.8% of the experimental group in Nitti et 
al. reported a positive treatment response after onabotulinumtoxinA while only 29.2% of placebo 
patients reported this response (p value < 0.001).  Sussman et al established an inverse 
correlation between I-QOL total scores and UI frequency with a Pearson’s correlation coefficient 
of -0.508 at week 12 establishing that decreased frequency in urinary incontinence events are 
associated with improved quality of life.       
 
CONCLUSIONS: Based on the three trials, onabotulinumtoxinA does improve quality of life in 
patients with urinary incontinence not adequately controlled with anticholinergics by improving 
patient satisfaction with treatment, urinary incontinence symptoms, and healthcare related quality 
of life.   
 
KEY WORDS: Urinary incontinence, Overactive bladder, OnabotulinumtoxinA 
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INTRODUCTION 
 
 Urinary incontinence (UI) is a condition in which there is an involuntary loss of urine and 
includes the classifications of stress, urge, overflow, and mixed incontinence.  Urge 
incontinence, which is also known as overactive bladder (OAB), is detrusor overactivity that 
results in uninhibited bladder contractions and subsequent leakage of urine.1  This paper 
evaluates three randomized, double blind, controlled trials comparing the efficacy of 
onabotulinumtoxinA for improving overall health related quality of life (HRQOL) in patients 
who have uncontrolled urge incontinence.  
 Overactive bladder is a disorder that is quite common in the medical field.  The incidence 
of urge urinary incontinence in the US is 2.6-14.2% in men and 8.9-36.3% in women with 
increasing incidence in females, increased age, increased BMI, and limited physical activity.1,2 
Incidence is expected to increase from 11.6% in 2013 to 23.6% in 2018.2  The estimated total 
national cost for urge urinary incontinence is $65.9 billion annually and is expected to increase 
due to the aging population.2  Overall, the mean annual cost of care for individual incontinence 
management is $751.3  The exact number of healthcare visits is unknown due to the fact that 
many patients do not report symptoms of urge urinary incontinence to their medical providers 
due to reasons such as embarrassment and lack of knowledge. 
 Symptoms of OAB include an intense urge to urinate, leakage of urine, and nocturia.  The 
etiology of urge incontinence is typically idiopathic but it can be also be contributed to bladder 
stones, bladder tumors, urinary tract infections, central nervous system lesions, or nerve injury.1  
These symptoms can have a profound impact on a patient’s life causing patients to avoid social 
situations, feel embarrassment, and prevent them from performing various activities.   
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 There are various methods that are utilized in order to treat urge incontinence.  Lifestyle 
modifications such as weight loss and caffeine reduction are helpful in patients whose symptoms 
are minor.  Kegel exercises with or without biofeedback can be done frequently to strengthen 
pelvic floor muscles, thus providing support and strength for the detrusor muscles.1  Bladder 
training or prompted voiding are other methods to alleviate symptoms.  The mainstay of drug 
therapy is antimuscarinic oral therapy, which is available in either short acting or long acting 
formulations.  Examples of such anticholinergic treatment are Tolterodine or Oxybutynin taken 
2-3 times per day1.  Other treatment includes onabotulinumtoxinA injections in the detrusor 
muscle, which is considered alternative treatment for refractory cases.  Adjunctive therapy such 
as alpha blockers and topical estrogens can also be utilized for effective treatment.1  If all of the 
aforementioned treatment fails, surgery and nerve stimulation can be performed. 
 There are various severities associated with urge urinary incontinence and the treatment 
options mentioned above have all been proven to be effective treatments.  Besides 
anticholinergic medications, there are limited pharmacological options for urinary incontinence.  
Intradetrusor injections of onabotulinumtoxinA has been utilized as an effective treatment for 
patients who have not had success with anticholinergic treatment.  Its effects and efficacy have 
been thoroughly studied and continue to be monitored, leading to the rise of its utilization in 
treatment for OAB patients. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not treatment with 
onabotulinumtoxinA improves the quality of life in patients with urinary incontinence not 
adequately controlled with anticholinergics. 
METHODS 
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 An established criteria was utilized for the selection of each study.  The chosen 
population was males and females 18-80 years old diagnosed with overactive bladder whose 
symptoms were not adequately managed with anticholinergic drug therapy.  The common 
intervention among all studies was intradetrusor injections of onabotulinumtoxinA in dosages of 
either 100, 200, or 300 units.  Patients received either 1 mL of onabotulinumtoxinA for 30 
intradetrusor injections or 0.5 mL for 20 intradetrusor injections.  Comparisons were made 
between the treatment group who received onabotulinumtoxinA and the experimental group of 
patients who received a placebo of normal saline administered via cystoscopy or intradetrusor 
injection.  The outcomes that were measured were the impact of onabotulinumtoxinA on the 
patient’s health related quality of life (HRQOL) and overall patient satisfaction with treatment.   
All 3 studies were randomized, double blind, placebo controlled clinical trials (RCT).  
Each article was published in a peer-reviewed journal and in the English language.  Key words 
that were utilized in searching include “urinary incontinence”, “overactive bladder”, and 
“onabotulinumtoxinA”.  Data sources for the systematic review were selected from PubMed by 
the author throughout December of 2013.  Articles were selected based on their relevance to the 
author’s clinical question and if they included patient oriented outcomes (POEM).  Inclusion 
criteria included RCTs that were published after 2007 and patients greater than 18 years old with 
overactive bladder.  Exclusion criteria included patients less than 18 years old and patients 
whose overactive bladder symptoms were controlled by anticholinergic therapy.  A summary of 
the statistics reported or used in the 3 RCTs include control event rate (CER), experimental event 
rate (EER), relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to 
treat (NNT), Pearson’s coefficient, confidence interval (CI), and p-values. 
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Table 1: Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Intervention 
Chanc-
ellor4 
(2013) 
RCT 416 18-80 -Age 18-80 years 
old with multiple 
sclerosis or spinal 
cord injury who 
had ≥ 14 urinary 
incontinence 
episodes/wk due to 
neurogenic 
detrusor 
overactivity 
-Symptoms not 
adequately 
controlled by 
anticholinergics 
-Patients with 
pelvic or urologic 
abnormalities 
-Previous 
botulinum toxin 
therapy for 
urologic 
conditions 
-Symptoms 
adequately 
controlled by 
anticholinergics 
17 30 intradetrusor 
injections (1 
mL each) of 
onabotulinum-
toxinA 200 or 
300 U 
Nitti5 
(2013) 
RCT 557 ≥ 18 - ≥ 18 years old 
with idiopathic 
overactive bladder  
- ≥ 3 urgency 
urinary 
incontinence 
episodes in a 3 day 
period 
-Average ≥ 8 
micturitions/day 
-Symptoms not 
adequately 
controlled by 
anticholinergics 
-Patients with a 
predominance of 
stress incontinence 
-Post void residual 
urine volume ≤ 
100 mL 
-Patients unwilling 
to perform clean 
intermittent 
catheterization if 
required 
65 20 intradetrusor 
injections (0.5 
mL each) of 
onabotulinum 
toxinA 100 U 
 
Suss-
man6 
(2013) 
RCT 275 18-80 -Age 18-80 years 
old with multiple 
sclerosis or spinal 
cord injury who 
had ≥ 14 urinary 
incontinence 
episodes/wk due to 
neurogenic 
detrusor 
overactivity 
-Symptoms not 
adequately 
controlled by 
anticholinergics 
-History of or 
current bladder 
conditions 
-Any surgeries that 
could affect 
bladder function 
-Previous 
botulinum toxin 
therapy for 
urologic 
conditions 
-24-hour total 
voided volume > 
3,000 mL 
-Post-void residual 
> 200mL 
0 30 intradetrusor 
injections (1 
mL each) of 
onabotulinum 
toxinA 200 or 
300 U 
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OUTCOMES MEASURED 
All outcomes that were measured were those of patient-oriented evidence (POEM) and 
were collected via patient-reported questionnaires.  For all 3 randomized clinical trials, 
questionnaires were filled out by patients repeatedly throughout the study at various post-
treatment visits.  Statistical analysis was performed on the intent-to-treat population. 
In both the Chancellor et al study and the Sussman et al study, the Incontinence Quality 
of Life Questionnaire (I-QOL), the Modified Overactive Bladder Patient Satisfaction with 
Treatment Questionnaire (OAB-PSTQ), and the Patient Global Assessment (PGA) were 
utilized.4,6  I-QOL is a 22 item questionnaire that assesses the impact of UI on a patient’s life.  
Scores range from 0-100 with higher scores reflecting better quality of life.4,6  Included in this 
questionnaire are the three other domain scores of avoidance and limiting behavior, psychosocial 
impact, and social embarrassment.4,6  OAB-PSTQ consists of 12 questions scored on a 6-point 
scale with lower scores reflecting greater satisfaction with treatment which assesses a 
medication’s impact on OAB symptoms, ability to interact in social situations, and cost.4,6  PGA 
is a scale that assesses patient’s symptoms, quality of life, activity limitations, and overall 
emotions related to urinary incontinence.6  Each item is scored on a scale from -7 (a very great 
deal worse) to +7 (a very great deal better).6   
 In the Nitti et al study, the King’s Health Questionnaire (KHQ), the Treatment Benefit 
Scale (TBS), and the I-QOL were utilized to assess patient’s overall satisfaction with treatment 
and quality of life.  KHQ assesses a patient’s perception of quality of life with UI, yielding two 
scores that were calculated using a series of formulas, with lower scores indicating better 
HRQOL.5  Part 1 assesses the patient’s general health and incontinence impact while part 2 
assesses quality of life, including physical and social limitations, relationships, emotions, sleep, 
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and severity.5  TBS assesses a patient’s perception of treatment benefit by rating the progress of 
their condition as either greatly improved, improved, not changed, or worsened.5 
RESULTS 
 In the 2013 study by Chancellor et al4, 407 patients with urinary incontinence received 
treatment with either 200 U onabotulinumtoxinA (n=135), 300 U onabotulinumtoxinA (n=132), 
or a placebo of 0.9% saline (n=149), with 399 patients remaining at the end of the 12 week study 
(98%).  No differences in efficacy were established between the two doses of 
onabotulinumtoxinA.4  Specifically, these patients had either multiple sclerosis or spinal cord 
injury, which contributed to their urinary incontinence, and had no other pelvic or urologic 
abnormalities nor prior treatment with botulinum toxin therapy.  Based on the I-QOL 
Questionnaire, there was a significant improvement in scoring, with a large percentage of 
patients having a ≥ 11 point increase from baseline after treatment with onabotulinumtoxinA as 
compared to placebo (p value < 0.001).  The domain scores of avoidance/limiting behavior, 
psychosocial impact, and social embarrassment also showed marked improvement after 
treatment with onabotulinumtoxinA as compared to placebo (p value < 0.001, 95% CI).  In 
relation to the OAB-PSTQ, improvement was shown by an increase in total scoring after 
treatment with onabotulinumtoxinA.  At the start of the trial, 45% of all the patients classified 
themselves as being somewhat or very satisfied with their current therapy, with this number 
increasing to 75% in the experimental group after treatment with onabotulinumtoxinA (see Table 
2).  Only 45% of patients at week 6 and 30% of patients at week 12 reported this level of 
satisfaction in the placebo group.  The PGA revealed that patients who received the placebo  
Table 2: Improvement of patient satisfaction and quality of life after treatment with 
onabotulinumtoxinA 
CER EER RBI ABI NNT P-value 
45% 75% 66.7% 30% 4 <0.001 
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showed no change in overall symptoms, QOL, activity limitations, or overall emotions while the 
experimental group with onabotulinumtoxinA reported improvements over time (p value ≤ 
0.001).4 
 Of the 557 randomized patients in the Nitti et al study5, 89% of patients who received 
100 U of onabotulinumtoxinA and 88% of patients who received 10 mL saline placebo 
completed the trial.  Overall, the patients had a mean duration of 6.7 years of OAB, an average 
use of 2.4 years worth of 2.5 anticholinergics prior to the study, and an average of 5.3 episodes 
of UI.  Nitti et al established that there was a statistically significant difference between 
onabotulinumtoxinA and placebo.5  Per the Treatment Benefit Scale, 60.8% of the experimental 
group reported a positive treatment response after onabotulinumtoxinA while only 29.2% of 
placebo patients reported this response (p value < 0.001) (See Table 3).  The Incontinence 
Quality of Life Questionnaire and the King’s Health Questionnaire showed large, clinically 
significant improvements in all domains after onabotulinumtoxinA compared to placebo 
treatment (p value < 0.001, 95% CI).  There was an improvement range of 19.6 to 23.9 ± SD 
change from baseline in the I-QOL score for the onabotulinumtoxinA treatment group and only a 
6.1-7.3 ± SD change from baseline for the placebo group.  Similar improvements were noted in  
Table 3: Improvement of patient satisfaction and quality of life after treatment with 
onabotulinumtoxinA 
CER EER RBI ABI NNT P-value 
29.2% 60.8% 108.2% 31.6% 4 <0.001 
 
the KQH.  Adverse effects were limited and most often occurred within the first 12 weeks of the 
study.  15.5% of onabotulinumtoxinA patients and 5.9% of placebo contracted an uncomplicated 
urinary tract infection not involving the upper urinary tract.  Other complications from the 
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onabotulinumtoxinA group included dysuria (12.2%), bacteriuria (5.0%), and urinary retention 
(5.4%).  Discontinuation rate due to adverse effects was 1.8% for the onabotulinumtoxinA group 
and 1.4% for the placebo group.  One death from the placebo group was reported but was 
unrelated to the treatment in this study.5   
 In the study by Sussman et al.6, 275 patients with either multiple sclerosis or spinal cord 
injury were randomized, with 92 receiving an intradetrusor placebo, 92 receiving 200 U of 
onabotulinumtoxinA, and 91 receiving 300 U of onabotulinumtoxinA.  Both doses of 
onabotulinumtoxinA effectively reduced episodes of urinary incontinence, deeming no 
differences in efficacy between the two doses of 200 U and 300 U.  For both doses of the 
experimental group of onabotulinumtoxinA, there was a significantly greater mean improvement 
in I-QOL total score (p value < 0.001) as well as in the domain scores for avoidance/limiting 
behavior, psychosocial impact, and social embarrassment (p value < 0.01) compared to the 
placebo group.  An inverse correlation between I-QOL total scores and UI frequency (Pearson’s 
correlation coefficient at week 6 being -0.483 and -0.508 at week 12) established that decreased 
frequency in urinary incontinence events were associated with improved quality of life.  The 
OAB-PSTQ also showed an overall improvement in total score compared to baseline for the 
onabotulinumtoxinA group versus placebo (p value < 0.001).  This questionnaire also reported 
that a greater percentage of patients post onabotulinumtoxinA treatment reported being 
“somewhat” or “very” satisfied with treatment and having “significantly met” or “exceeded” 
expectations for their treatment compared to placebo (p value < 0.001) (see Table 4).   
Table 4: Improvement of patient satisfaction and quality of life after treatment with 
onabotulinumtoxinA 
CER EER RBI ABI NNT P-value 
39.5% 77.5% 96.2% 38% 3 <0.001 
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81.9% of patients receiving placebo by week 12 reported no side effects while only 62.0%-
63.5% of the onabotulinumtoxinA patients reported no side effects.  Similar findings from the 
Patient Global Assessment showed that the patients receiving onabotulinumtoxinA reported 
improvement in quality of life than those who received placebo.6 
DISCUSSION 
 The goal of this systemic review was to determine whether or not onabotulinumtoxinA 
improves the quality of life in patients who have urinary incontinence, specifically overactive 
bladder whose symptoms were not adequately controlled with anticholinergic treatment.  Urinary 
incontinence is an emotionally debilitating condition that has profound effects on a person’s 
quality of life due to embarrassment, fear of UI episodes occurring in public, as well as due to 
added medical complications and costs.  Therefore, adequate treatment is significantly correlated 
with regards to quality of life.  Due to the fact that there are few pharmacological treatments 
besides anticholinergics for overactive bladder, it is important to establish that 
onabotulinumtoxinA causes a statistically significant improvement in quality of life.  All three 
randomized controlled trials were able to establish this correlation between onabotulinumtoxinA 
and quality of life. 
OnabotulinumtoxinA, brand name Botox in the United States, is a an FDA approved 
neurotoxin that is produced by the anaerobic bacillus Clostridium botulinum.7  Its mechanism of 
action is that it prevents the release of acetylcholine, producing a state of denervation.7  
Specifically, onabotulinumtoxinA targets the efferent pathways of detrusor activity as well as 
various targets in the bladder wall that may contribute to overactive bladder.5  Its uses are 
indicated for bladder dysfunction, including detrusor overactivity and overactive bladder, 
blepharospasm, cervical dystonia, chronic migraines, focal spasticity, strabismus, primary 
Kopec, Incontinence & OnabotulinumtoxinA 10 
axillary hyperhidrosis, and for cosmetic uses to reduce facial lines.7  There is a black box 
warning due to the potential of the toxin to spread beyond the area of injection within hours to 
weeks after injection, leading to toxin effects, including potentially fatal swallowing and 
breathing difficulties.7  A three day discontinuation of antiplatelet therapy and three days worth 
of prophylactic antibiotic therapy should be given prior to and after the administration of 
intradetrusor onabotulinumtoxinA to decrease the risk of urinary tract infection.7  
OnabotulinumtoxinA should not be administered via intradetrusor injection to any patient with a 
urinary tract infection, urinary retention, or in a patient with a post-void residual volume > 200 
mL who is not utilizing self-catheterization.7  OnabotulinumtoxinA is widely available in the US 
and is covered by most major insurance plans, including Medicare and Medicaid, with various 
programs available to help off-set any remaining out of pocket costs.  Its use has been increasing 
in various specialties of medicine and as alternative treatment for many disorders. 
There were various limitations to the RCTs utilized in this systematic review.  Both 
Chancellor et al. and Sussman et al. used the PGA which is not a validated measure for patients 
with neurogenic detrusor overactivity due to spinal cord injury.4,6  Another limitation was that 
the data utilized in Chancellor et al. cannot be generalized to patients with idiopathic overactive 
bladder.4  Not all patients completed the OAB-PSTQ at each treatment visit by Sussman et al. 
which could subsequently alter their results.6  For all studies, it was indicated that some patients 
needed to initiate clean-catch intermittent catheterization (CIC) because treatment with 
onabotulinumtoxinA has the potential to compromise bladder emptying.  According to 
Chancellor et al., this did not have a negative impact on treatment benefit with 
onabotulinumtoxinA due to similar improvements in HRQOL assessments between patients who 
did and did not require CIC.6 
Kopec, Incontinence & OnabotulinumtoxinA 11 
CONCLUSION 
 The results of the three randomized clinical trials demonstrated that treatment with 
onabotulinumtoxinA does improve the quality of life in patients with urinary incontinence not 
adequately treated with anticholingergics.  Along with the clinical aspects of reduced weekly 
urinary incontinence episodes and improved urodynamics, patients reported increased treatment 
satisfaction and as well as treatment goal attainment, ultimately improving their quality of life 
and allowing them to live more fulfilled lives both emotionally and physically.  An increasing 
number of recent studies have found similar findings and more studies are continuing to further 
explore the efficacy of onabotulinumtoxinA.  Future exploration with onabotulinumtoxinA 
should involve other types of urinary incontinence such as stress or overflow.  Further research is 
warranted to see if there is a synergistic effect between treatment with both onabotulinumtoxinA 
and anticholinergics.       
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